US 11,891,369 B2
Compounds for binding proprotein convertase subtilisin/kexin type 9
Anjali Pandey, Fremont, CA (US); Simeon Bowers, Oakland, CA (US); Thomas E. Barta, Carrboro, NC (US); and Jonathan William Bourne, Fairport, NY (US)
Assigned to SRX Cardio, LLC, Pittsford, NY (US)
Filed by SRX Cardio, LLC, Pittsford, NY (US)
Filed on Apr. 28, 2020, as Appl. No. 16/861,166.
Application 16/861,166 is a continuation of application No. 16/078,578, abandoned, previously published as PCT/US2017/019189, filed on Feb. 23, 2017.
Claims priority of provisional application 62/298,920, filed on Feb. 23, 2016.
Prior Publication US 2021/0032214 A1, Feb. 4, 2021
Int. Cl. A61K 31/4709 (2006.01); C07D 295/073 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 211/18 (2006.01); C07D 211/26 (2006.01); C07D 211/46 (2006.01); C07D 211/54 (2006.01); C07D 211/58 (2006.01); C07D 295/195 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 407/02 (2006.01); C07D 417/04 (2006.01); C07D 417/14 (2006.01); C07D 471/08 (2006.01)
CPC C07D 295/073 (2013.01) [C07D 211/18 (2013.01); C07D 211/26 (2013.01); C07D 211/46 (2013.01); C07D 211/54 (2013.01); C07D 211/58 (2013.01); C07D 295/195 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 405/14 (2013.01); C07D 407/02 (2013.01); C07D 417/04 (2013.01); C07D 417/14 (2013.01); C07D 471/08 (2013.01)] 5 Claims
 
1. A method of treating a disease or condition, wherein the disease or condition is selected from hypocholesterolemia, coronary disease, hypertension, hypercholesterolemia, atherosclerosis, and diabetes, the method comprising administering to a patient in need thereof a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein:
m is 0, 1, or 2;
X1 is N;
X2, X3, and X4 are each independently CR2 or CR2R2;
ring B is a six-membered ring comprising one or more double bonds;
X5 and X6 are CR2;
X7 is C;
ring A is:

OG Complex Work Unit Chemistry
where the wavy line in ring A indicates the point of attachment to

OG Complex Work Unit Chemistry
L is a bond;
R1 in each instance is independently halo or C1-6 alkyl optionally substituted with halo or hydroxy;
R2 in each instance is independently hydrogen, halo, or C1-6 alkyl optionally substituted with halo or hydroxy
R3 is halo, C1-6 alkyl, C3-6 cycloalkyl, or aryl;
wherein each C1-6 alkyl, C3-6 cycloalkyl, or aryl of R3 is optionally substituted with 1 to 3 substituents independently selected from halo and hydroxy; and
R4 is hydrogen or C1-6 alkyl;
provided that when A is attached via a carbon atom to the remainder of the molecule and m is other than 0, then R1 is not appended to the same carbon atom.